
Overview
Human Biome is focused on research related to the gut microbiome and aims to create next-generation biotherapeutics for more effective disease treatment and health restoration. The company combines science and technology in its projects, which include a microbiota bank.
Financials
Revenue history (in k)
From the notes
| Current income tax (CIT due) | $0 |
Filing timeliness
4 of 4 financial statements were filed late (the longest delay 83 days for 2025). All were audited by a statutory auditor.
- 202506/10/2026
- 202416/07/2025
- 202301/08/2024
- 202205/09/2023
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.
Results vs industry
News

Human Biome S.A. received financial support under the European Funds for a Modern Economy programme

Human Biome S.A. secures 2nd tranche of the Series A round

We close the first tranche of the Series A round and raise USD 4 million to develop biosynthetic microbiome

Human Biome S.A. to receive support under the European Funds for a Modern Economy programme

Human Biome Institute featured in the Top Disruptors in Healthcare report
Industry
Offer
- Microbiome medicines
- Microbiome therapeutics
- Microbiome research
- Genomic analyses
- Biobank services
- Development of biological therapies
Websites
- human-biome.comHuman Biome | Next-Generation Microbiome TherapeuticsWordPress 7.1Nginx
Public procurement
20 tenders recorded as contractor: 10 national ($726,913) and 10 EU ($291,158).
| Publication date | Subject | Amount | Contracting authority | |
|---|---|---|---|---|
| Sep 4, 2026 | Stool processing service for intestinal microbiota transfer | –– | Samodzielny Publiczny Zakład Opieki Zdrowotnej Uniwersytecki Szpital Kliniczny Nr 1 Im. Norberta Barlickiego Uniwersytetu Medycznego w Łodzi | |
| Aug 10, 2026 | Successive supply of pharmaceutical products to Wojewódzki Szpital Zespolony w Kaliszu | $14,317$14,317 | Wojewódzki Szpital Zespolony Im. Ludwika Perzyny w Kaliszu | |
| Jul 24, 2026 | Supply of medicines, foodstuffs for special medical purposes and pharmaceutical ingredients – 27 lots. | $35,367$35,367 | Szpital Kliniczny Im. Karola Jonschera Uniwersytetu Medycznego Im. Karola Marcinkowskiego w Poznaniu |
The company is the contractor in 18 public sector contracts, worth USD 145.42k in total. They were signed with 14 public buyers.
| Signed on | Subject | Amount | Public buyer | |
|---|---|---|---|---|
| Nov 10, 2026 | Intestinal microbiota processing service | $19,271 | Szpital Specjalistyczny w Brzozowie Podkarpacki Ośrodek Onkologiczny Im.Ks.B.Markiewicza | |
| Nov 6, 2026 | Processing service for gut microbiota MBiotix HBI | $789.29 | Samodzielny Publiczny Zespół Zakładów Opieki Zdrowotnej w Nisku | |
| Oct 8, 2026 | Mbiotix | $970.83 | Szpital Św. Anny w Miechowie |
Authorized Representatives
Manner of representation
In the case of a one-person management board, the sole member of the management board is entitled to make declarations of will concerning the company’s rights and obligations on behalf of the company. In the case of the appointment of a multi-member management board, each member of the management board is entitled to make declarations of will concerning the company’s rights and obligations on behalf of the company independently.
Supervisory board
Beneficial owners
| Person | Rights |
|---|---|
Bank accounts
Registered as a VAT taxpayer on 2020-03-20.
71 1050 1764 1000 0090 8632 5561
47 1050 1764 1000 0090 8097 3630
74 1050 1764 1000 0090 8592 9553
Debt
No entries in the National Debtors Register (KRZ).
MSiG notices
| Publication date | Event | |
|---|---|---|
| Dec 1, 2022 | Transformation registered |
Public aid
4 public aid cases recorded, with a total value of $4,743,832.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Feb 25, 2026 | De minimis aid (in accordance with Commission Regulation 2023/2831) | –– | Prezes Polskiej Agencji Rozwoju Przedsiębiorczości | |
| Nov 20, 2025 | Aid for research and development projects: industrial research | –– | Dyrektor Narodowego Centrum Badań i Rozwoju | |
| Nov 20, 2025 | Aid for research and development projects: experimental development | –– | Dyrektor Narodowego Centrum Badań i Rozwoju |
European Funds
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2026-01-01 | Development of an advanced FMT formulation – an ecobiotic containing concentrated and preserved human gut microbiota with an extracellular matrix for increased stability, viability and efficacy in the treatment of CDI infections | $6.5M$6,511,122 | European Funds for a Modern Economy | |
| 2025-09-01 | Preparation of an application for a Eurogrant planned under the EIC pre-accelerator - Widening programme | $17,431$17,431 | European Funds for a Modern Economy | |
| 2022-02-01 | Preparation of application documentation for the project provisionally titled: “Development of a next-generation biotherapeutic based on components of the gut microbiota to combat antimicrobial resistance”, planned for implementation under the EIC Pathfinder Open programme | $5,215$5,215 | Operational Programme Smart Growth |
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
| BDO register entry | Active |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Scope Fluidics S.A. | $1,264,188.85 | scopefluidics.com | ||
| Śląski Park Technologii Medycznych Kardio-Med Silesia sp. z o.o. | $969,037.30 | kmptm.pl | ||
| Nanogroup S.A. | $843,099.47 | nanogroup.eu | ||
| Bioresearch Group sp. z o.o. | $776,186.19 | bioresearch.pl | ||
| Simbec-Orion (Pol) sp. z o.o. | $631,143.10 | simbecorion.com | ||
| Precisionlife Poland sp. z o.o. | $617,020.34 | precisionlife.com | ||
| Camino Science sp. z o.o. | $557,065.18 | camino.science | ||
| Prolab sp. z o.o. + limited partnership | $496,608.00 | pro-lab.pl | ||
| Vaxican sp. z o.o. | $390,933.79 | vaxican.com | ||
| Medicofarma Biotech S.A. | $314,882.33 | medicofarmabiotech.pl |
Change history
| Date | Event | |
|---|---|---|
| 2026-08-26 | Share capital increase (142,169.50 PLN → 160,774.20 PLN) | |
| 2026-03-26 | Share capital increase (123,564.90 PLN → 142,169.50 PLN) | |
| 2025-07-17 | Name change (Human Biome Institute → Human Biome) | |
| 2025-02-04 | Share capital increase (116,300.00 PLN → 123,564.90 PLN) | |
| 2023-09-21 | Share capital increase (110,500.00 PLN → 116,300.00 PLN) |
FAQ
Last updated: 2026-10-06